Rockland Immunochemicals

Rockland Immunochemicals

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Rockland Immunochemicals is a mature, revenue-generating provider of antibodies and specialized research services, leveraging over 60 years of experience in immunochemistry. The company has evolved from a traditional antibody supplier into a specialized partner for the rapidly growing RNA therapeutics field, offering innovative tools like its sequence-independent ModDetect™ panels for nucleic acid modification detection. Its business model combines the sale of catalog reagents with high-margin custom antibody development, protein characterization, and assay development services, positioning it as an enabler for both academic research and biopharmaceutical R&D.

Antibodies

Technology Platform

Proprietary immunochemistry and hybridoma development for antibody production, combined with the ModDetect™ platform for sequence-independent detection of nucleic acid modifications in oligonucleotides.

Opportunities

The explosive growth of the RNA therapeutics market (ASOs, siRNA, mRNA) creates a high-demand niche for specialized analytical tools and services.
Rockland's ModDetect™ platform and custom antibody services are uniquely positioned to address the sequence-independent detection and bioanalysis challenges in this field, offering a significant premium growth opportunity.

Risk Factors

Key risks include dependence on cyclical academic research funding, intense competition in the antibody and bioanalytical services market, and the potential slow adoption of its novel immunoassay platform by biopharma companies accustomed to traditional oligonucleotide analysis methods.
Operational execution risk on custom projects is also ever-present.

Competitive Landscape

Rockland competes in the broad life science research tools market against giants like Thermo Fisher Scientific, Abcam, and Bio-Techne, as well as numerous niche antibody producers. Its differentiation lies in its deep custom service capabilities, long-standing reputation for quality, and its novel focus on immunoassays for oligonucleotide analysis, a less crowded segment compared to traditional antibody reagents.